Latest Headlines

  1. Avalon’s Laboratory Services MSO Acquires California-Based Medical Supply Company And Proprietary FDA-Registered External Male Catheter Device 9/13/2023

    Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative precision diagnostics and provider of clinical laboratory services, today announced Laboratory Services MSO, LLC (“LSM”), has acquired Merlin Medical Supply (“MMS”), a profitable, well-established Home Medical Equipment (“HME”) and Durable Medical Equipment (“DME”) company providing acute and non-acute medical supplies in Ventura County, California.

  2. Devyser And Thermo Fisher Scientific Collaborate To Promote Laboratory Services To Advance Pharmaceutical Research 9/13/2023

    Devyser and Thermo Fisher Scientific have entered into a collaboration agreement to promote laboratory services. The goal is to partner with pharmaceutical companies to support their development projects utilising Devyser's unique assays in its CLIA-certified laboratory.

  3. Laboratorio Curie Expands Relationship With SOPHiA GENETICS 9/13/2023

    SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, has expanded its relationship with Laboratorio Curie, a leading laboratory located in the capital city of Paraguay.

  4. Adaptive Announces Launch Of Epic Integration For clonoSEQ® 9/13/2023

    Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced that clonoSEQ® is now available to health care providers as a fully integrated test in Aura, Epic’s specialty diagnostics suite.

  5. AXIM Biotechnologies Develops First Non-Invasive, Rapid, Point-Of-Care, Diagnostic Test For Parkinson’s Disease 9/12/2023

    AXIM Biotechnologies, Inc (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare diagnostic solutions development company, announced today that it has successfully developed the world’s first rapid, point-of-care, non-invasive diagnostic assay for the detection of abnormal alpha-synuclein, a known biomarker for Parkinson’s Disease (PD).

  6. Artyc Launches Medstow Mini For Temperature Stable Blood Sample Collection And Delivery 9/12/2023

    Artyc PBC, a California-based cold chain startup, announced today the launch of Artyc's Medstow Mini, a small battery-powered cooling container designed to transport medical goods through the supply chain.

  7. Exai Bio Presents Data Further Validating Its Liquid Biopsy Platform At The 2023 World Conference On Lung Cancer 9/12/2023

    Exai Bio today announced non-small cell lung cancer (NSCLC) data further validating that its novel RNA- and generative AI-based liquid biopsy platform detected early-stage disease with high accuracy.

  8. Mercy BioAnalytics Adds Marketing And Portfolio Management Leadership To Support Diagnostic Test Development And Commercialization 9/11/2023

    Mercy BioAnalytics, Inc., a pioneer in extracellular vesicle-based liquid biopsies for the early detection of cancer, today announced that it has added two senior executives to the Company’s leadership team as it continues development of its diagnostic test portfolio and looks ahead to commercialization.

  9. MGI Launches The DCS Lab Initiative To Expand Global Omics Access And Capabilities 9/11/2023

    MGI, a company committed to building core tools and technology to lead life science, today announced the DCS Lab Initiative to help facilitate large-scale leading multi-omics laboratories and spur critical scientific research.

  10. Lucid Diagnostics Releases Positive Data From First Prospective Clinical Utility Study Of EsoGuard®Esophageal Precancer Detection 9/7/2023

    Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ( "PAVmed"), today announced it has released positive interim data from the multicenter, CLinical Utility of EsoGuard (CLUE) study.